

CHM RABBIT PAB

货号: S221731

产品全名: CHM 兔多抗

基因符号 TCD; GGTA; REP-1; DXS540; HSD-32

UNIPROT ID: P24386 (Gene Accession - NP_000381)

背景: This gene encodes component A of the RAB geranylgeranyl transferase holoenzyme. In the dimeric holoenzyme, this subunit binds unprenylated Rab GTPases and then presents them to the catalytic Rab GGase subunit for the geranylgeranyl transfer reaction. Rab GTPases need to be geranylgeranylated on either one or two cysteine residues in their C-terminus to localize to the correct intracellular membrane. Mutations in this gene are a cause of choroideremia; also known as tapetochoroidal dystrophy (TCD). This X-linked disease is characterized by progressive dystrophy of the choroid, retinal pigment epithelium and retina. Alternatively spliced transcript variants have been found for this gene.

抗原: Synthetic peptide of human CHM

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 50-200; ELISA: 5000-10000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Signal Transduction, Neuroscience


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human colorectal cancer tissue using 221731(CHM Antibody) at a dilution of 1/85(Cytoplasm).



In comparison with the IHC on the left, the same paraffin-embedded Human colorectal cancer tissue is first treated with the synthetic peptide and then with 221731(Anti-CHM Antibody) at dilution 1/85.



The image on the left is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using 221731(Anti-CHM Antibody) at a dilution of 1/85.



In comparison with the IHC on the left, the same paraffin-embedded Human gastric cancer tissue is first treated with synthetic peptide and then with D268481(Anti-CHM Antibody) at dilution 1/85.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
